Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. (2022)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02437-5
PubMed Identifier: 34953525
Publication URI: http://europepmc.org/abstract/MED/34953525
Type: Journal Article/Review
Volume: 399
Parent Publication: Lancet (London, England)
Issue: 10323
ISSN: 0140-6736